 | |
| Clinical data | |
|---|---|
| Other names | βk-5Br-NM-αMT; β-Keto-5-bromo-N-methyl-αMT; β-Keto-5-bromo-N-methyl-AMT; α,N-Dimethyl-5-bromo-β-ketotryptamine; β-Oxo-5-bromo-α-methyl-NMT |
| Drug class | Monoamine releasing agent |
| Identifiers | |
| |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C12H13BrN2O |
| Molar mass | 281.153 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BK-5Br-NM-AMT, orβk-5Br-NM-αMT, also known asβ-keto-5-bromo-N-methyl-αMT orα,N-dimethyl-5-bromo-β-ketotryptamine, is amonoamine releasing agent of thetryptamine,α-alkyltryptamine, andβ-ketotryptamine families.[1]
It is known to induce the release ofserotonin anddopamine, with respectiveEC50Tooltip half-maximal effective concentration values of 295 nM and 2,100 nM in rat brainsynaptosomes, whereasnorepinephrine release was not reported.[1] In contrast to many other tryptamines, the drug is inactive as anagonist ofserotonin receptors including the5-HT1,5-HT2, and5-HT3 receptors.[1] In addition, unlike other α-alkyltryptamines likeα-methyltryptamine (αMT), it is inactive as amonoamine oxidase inhibitor (MAOI).[1]
BK-5Br-NM-AMT was first described in the literature by 2023.[1] It waspatented byMatthew Baggott andTactogen as a potential novelentactogen.[1] BK-5Br-NM-AMT is the 5-bromoderivative ofBK-NM-AMT.[1][2][3][4] Otheranalogues of the drug includeBK-5F-NM-AMT andBK-5Cl-NM-AMT.[1]